HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Online-Only Appendix Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kang, E. S. Articles by Lee, H. C. Search for Related Content PubMed PubMed Citation Articles by Kang, E. S. Articles by Lee, H. C. Social Bookmarking                What's this?

The Influence of Adiponectin Gene Polymorphism on the Rosiglitazone Response in Patients With Type 2 Diabetes

¹ Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
² Department of Internal Medicine, Kwandong University College of Medicine, Gangneung, Korea
³ Department of Internal Medicine, Inha University College of Medicine, Incheon, Korea

Address correspondence and reprint requests to Hyun Chul Lee, Department of Internal Medicine, Yonsei University College of Medicine, 134 Shinchon-Dong Seodaemun-Gu, Seoul, 120-752, Korea. E-mail: endohclee{at}yumc.yonsei.ac.kr

	ABSTRACT

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
OBJECTIVE —The aim of this study was to examine the effects of rosiglitazone on adiponectin and plasma glucose levels in relation with common adiponectin gene (ACDC) polymorphisms.

RESEARCH DESIGN AND METHODS —A total of 166 patients with type 2 diabetes were treated with rosiglitazone (4 mg/day) for 12 weeks without changing any of their previous medications. In all, single nucleotide polymorphism (SNP)45 and SNP276 of ACDC were examined.

RESULTS —Regarding SNP45, there was a smaller reduction in the fasting plasma glucose (FPG) level and the HbA_1c value in the carriers of the GG genotype than in the carriers of the other genotypes (P = 0.031 and 0.013, respectively). There was a smaller increase in the serum adiponectin concentration for the GG genotype than for the other genotypes (P = 0.003). Regarding SNP276, there was less reduction in the FPG level for the GG genotype than for the other genotypes (P = 0.001). In the haplotype analysis, the reductions in the FPG and HbA_1c levels were smaller for the GG homozygote haplotype than for the other haplotypes (P = 0.001 and 0.001, respectively). The increase in the plasma adiponectin concentration for the GG homozygote haplotype was smaller than that of the other haplotypes (P = 0.003).

CONCLUSIONS —These data suggest that genetic variations in the adiponectin gene can affect the rosiglitazone treatment response of the circulating adiponectin level and blood glucose control in type 2 diabetic patients.

Abbreviations: FPG, fasting plasma glucose • HOMA-IR, homeostasis model assessment of insulin resistance • PPAR, peroxisome proliferator–activated receptor • PPRE, PPAR responsive element • SNP, single nucleotide polymorphism.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
Adiponectin is a circulating protein secreted by adipocytes and is associated with the development of insulin resistance and atherosclerosis (1, 2). Serum adiponectin concentrations are lower in patients with type 2 diabetes, obesity, and coronary heart disease than in healthy subjects (3,4). This molecule is known to be a potent insulin sensitizer. Thiazolidinediones lower the blood glucose level primarily by activating the peroxisome proliferator–activated receptor (PPAR)-, which then improves insulin sensitivity (5). The synthetic PPAR- agonist, rosiglitazone, is reported to increase the serum adiponectin level in type 2 diabetes (6).

Adiponectin is encoded by ACDC, which is located on chromosome 3q27 (7,8). Studies of ACDC mutations have revealed 16 single nucleotide polymorphisms (SNPs) (9). Among them –11377, +45, and +276 have been reported to be associated with type 2 diabetes, circulating adiponectin levels, and insulin resistance in a Japanese population (10,11). However, previous studies on the association between ACDC SNPs, type 2 diabetes, and adiponectin levels have shown that the specific SNPs associated with this process differ according to both the study and the ethnic population. The aim of this study was to examine the association between SNPs in ACDC and the response to rosiglitazone. In addition, this study also investigated the PPAR responsive element (PPRE) polymorphism in the ACDC promoter.

	RESEARCH DESIGN AND METHODS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
A total of 166 patients were treated with rosiglitazone (4 mg/day) during a 12-week treatment course without changing previous medications. Type 2 diabetic patients with a HbA_1c values of 7.5–11.5% and fasting plasma glucose (FPG) levels of 7.8–14.0 mmol/l; (140–252 mg/dl) were enrolled in this study. The inclusion criteria were 1) age 35–80 years, 2) BMI 18.5–30 kg/m², 3) no history of PPAR agonist use, 4) no medication changes in the previous 3 months, and 5) for women, postmenopausal or using appropriate contraceptive methods. Patients with type 1 diabetes, any history of ketoacidosis, ischemic heart disease, or congestive heart failure (New York Heart Association II–IV) or who were receiving insulin therapy and pregnant or lactating women were excluded from this study. The patients were advised to consume a fixed-calorie diet and maintain a constant level of physical activity throughout the study. The Institutional Review Board of Yonsei University College of Medicine approved the study protocol. All subjects were provided adequate information about this study and gave their informed consent.

Clinical laboratory tests
Blood samples were collected after an overnight fast. The FPG and total cholesterol and triglyceride levels were determined using an enzymatic colorimetric assay. The HDL cholesterol concentration was measured using lipoprotein electrophoresis. The LDL cholesterol level was calculated using the Friedewald formula (12). The insulin concentration was measured using a radioimmunoassay kit (DAINABOT, Tokyo, Japan). The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated by the formula: (fasting insulin [microunits per milliliter] x fasting glucose [millimoles per liter])/22.5. The HbA_1c value was determined using a high-performance liquid chromatography method (Varient II; GREENCROSS, Seoul, Korea). The serum adiponectin concentration was measured using a commercial radioimmunoassay kit (Linco Research, St. Charles, MO).

Genotyping
SNP45 and -276 were chosen because they are common (frequency >20%) in Korean type 2 diabetic patients and have been reported to be associated with type 2 diabetes in other Asian populations (10,11). SNP-11377 was also genotyped. The genomic DNA was extracted from leukocytes in the whole-blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA). PCR amplification was performed in a total volume of 20 µl containing the PCR buffer (10 x Optiperform Buffer III of 40 mmol/l KCl, 10 mmol/l Tris-HCl, 1.5 mmol/l MgCl₂), 45 ng/µl genomic DNA, 1 unit of Taq DNA polymerase, 250 µM concentrations each dNTPs, and 10 pmol of the sense and antisense primers. The PCR conditions and primer sequences used for ACDC PPRE, SNP45 and SNP276 are shown in the online appendix (available at http://care.diabetesjournals.org). The PCR products were genotyped by sequencing with an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA).

Statistical analysis
Data are shown as means ± SD. All calculations and statistical analyses were performed using the SPSS for Windows software (version 12.0; SPSS, Chicago, IL). A paired t test was used to evaluate the effects of rosiglitazone on the metabolic parameters. Comparisons of the continuous variables among the genotypes were assessed using an ANOVA test, and a post hoc Bonferroni correction was made to control the effects of multiple comparisons. The statistical analysis of triglyceride, HDL cholesterol, fasting insulin, and HOMA-IR levels was performed using log-transformed values because the distribution was not normal. P values <0.05 were considered significant. The allelic distribution of each SNP was verified using Hardy-Weinberg equilibrium. The haplotypes at locus 45 and locus 276 for each individual were inferred by a maximum likelihood estimation method with the Haplotyper program (http://www.people.fas.harvard.edu/junliu/Haplo).

	RESULTS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
Table 1 shows the allele, genotype, and haplotype distribution of ACDC. No significant deviation from Hardy-Weinberg equilibrium was observed for either locus. Table 2 shows the clinical characteristics of the patients before and after rosiglitazone treatment. The FPG levels and HbA_1c values were significantly lower after 12 weeks of treatment compared with the baseline. The serum adiponectin concentration was significantly higher after the rosiglitazone treatment (5.30 ± 4.79 µg/ml vs. 9.92 ± 6.81 µg/ml, P < 0.001). No mutation was observed at the PPRE of the adiponectin gene promoter region in any of 166 patients. Tables 3 and 4 show the clinical and biochemical characteristics of the patients according to the SNP45 and SNP276 genotypes. There were no significant differences in terms of age, duration of diabetes, and BMI according to the SNP45, SNP276, and SNP-11377 genotypes. The FPG levels, HbA_1c values, and the plasma lipid profiles were not significantly different among the genotypes of SNP45, SNP276, and SNP-11377 at baseline (Tables 3 and 4 and online appendix Table A-3, respectively).

There were no significant differences in terms of insulin resistance, decrease in the FPG, decrease in the HbA_1c, and increase in the serum adiponectin levels according to SNP-11377 genotype (data are shown in the online appendix Table A-3).

In the haplotype analysis, the degree of the decrease in the FPG level was smaller in those with the GG homozygote haplotype than in those with the other haplotypes (GG homozygote haplotype, 0.03 ± 3.15 mmol/l; other haplotypes, 1.69 ± 2.40 mmol/l; P = 0.001) (Table 5). The patients with the GG homozygote haplotype had a smaller decrease in the HbA_1c level than those with the other haplotypes (GG homozygote haplotype, 0.18 ± 1.23%; other haplotypes, 0.85 ± 1.05%; P = 0.001) (Table 5). In addition, the degree of the increase in the serum adiponectin level after the rosiglitazone treatment was less in those patients with the GG homozygote haplotype than the subjects with the other haplotype (GG homozygote haplotype, 0.82 ± 3.62 µg/ml; other haplotypes, 4.81 ± 5.07 µg/ml; P = 0.003) (Table 5).

	CONCLUSIONS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
Recently, Iwaki et al. (13) characterized the PPAR- binding site, PPRE, in the human adiponectin gene promoter. Although a great deal of effort has been made to identify the mutation in this region, this study could not detect any mutation in the 166 type 2 diabetic patients examined.

Previous studies have shown that thiazolidinediones increase the serum adiponectin concentration by increasing the level of adiponectin transcription (14,15). Also, the association between an adiponectin gene polymorphism and the risk of type 2 diabetes has been examined in many studies (9–11,16). SNP45 and SNP276 were reported to be associated with type 2 diabetes in a Japanese population (10), whereas it was reported that SNP-11391 and SNP-11377 were related to type 2 diabetes in a French population (16). Therefore, the SNPs of ACDC for type 2 diabetes and insulin resistance appear to be different among different populations. This prospective intervention study was performed to evaluate how rosiglitazone response varies with adiponectin gene polymorphisms.

Our data suggest that there is no association between SNP-11377 genotype and rosiglitazone response, but patients with the GG genotype at SNP45 and/or the GG genotype at SNP276 are unlikely to respond to rosiglitazone. In addition, a smaller increase in the serum adiponectin concentration was observed in patients with the SNP45 GG genotype than for those with the other genotypes. It was also observed that the degree of the decrease in the FPG level and HbA_1c value was smaller in the patients with the GG homozygote haplotype than in those with the other haplotypes. In addition, patients with the GG homozygote haplotype had a smaller degree of increase in the serum adiponectin levels than in those with the other haplotypes. Patients with the GG homozygote haplotype are unlikely to respond to rosiglitazone.

The ACDC SNP45 is located in exon 2 and is a silent mutation for Gly15 (GGT to GGG). However, it might inactivate the gene or affect the adiponectin concentration by influencing the pre-mRNA splicing or the stability of the mRNA (17). Alternatively, it may be related to another functional locus via a linkage disequilibrium not yet identified. SNP276 is located in intron two of ACDC. The intronic SNP can affect the expression level of the gene via an unknown mechanism. There may be a specific linkage structure or gene-environmental interaction.

Although baseline and posttreatment FPG, HbA_1c, and serum adiponectin levels were not significantly different between the GG homozygote haplotype and the other haplotypes, there were significant differences in the changes of the FPG, HbA_1c, and serum adiponectin levels. The difference in either the adiponectin transcription activity or the adiponectin mRNA stability according to the ACDC genotypes could be responsible for the reduced serum adiponectin concentration in the GG homozygote haplotype compared with the other haplotypes. A low adiponectin level in patients with the GG homozygote haplotype may result in increased insulin resistance, which in turn contributes to a smaller decrease in the FPG levels and HbA_1c values by several mechanisms (18,19). Multiple regression tests were performed and revealed that age, sex, and BMI were not found to be major confounding factors of serum adiponectin levels according to the ACDC genotypes (data shown in online appendix).

Our findings are in contrast to those reported by Yang et al. (20), who found that subjects with the TT genotype at SNP45 are associated with insulin resistance. This discrepancy could be due to the different study population. Yang et al. (20) examined nondiabetic subjects, which is in contrast to the diabetic patients in this study. Moreover, they used HOMA-IR as an index of insulin resistance, which is not believed to be an accurate indicator for insulin resistance in patients with a low BMI and insulin secretory defect (21). Menzaghi et al. (22) reported that subjects with the TT genotype at SNP276 had a higher serum adiponectin level than the other genotypes. However, no difference was observed in the serum adiponectin level at the baseline among the SNP276 genotypes in this study. This discordance could be explained by differences in the ethnicity or specific study population.

In conclusion, this study suggests that patients with G allele homozygosity at locus 45 and locus 276 are unlikely to respond to rosiglitazone. It was found that variations in the adiponectin gene could affect the rosiglitazone treatment response to the serum adiponectin level and blood glucose control. These findings may be clinically relevant in the prediction of patients who will best respond to rosiglitazone treatment. However, further investigations will be needed to elucidate the functional mechanism of these polymorphisms.

	Acknowledgments

 
This study was supported by the Brain Korea 21 Project for Medical Science, Yonsei University, and by Grant 03-PJ10-PG13-GD01-0002 from the Korea Health 21 R&D Project, Ministry of Health and Welfare.

	Footnotes

 
Additional information for this article can be found in an online appendix at http://care.diabetesjournals.org.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received for publication August 16, 2004. Accepted for publication January 23, 2005.

	References

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 

1. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473–2476, 1999[Abstract/Free Full Text]
   
2. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-B signaling through a cAMP-dependent pathway. Circulation 102:1296–1301, 2000[Abstract/Free Full Text]
   
3. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935, 2001[Abstract/Free Full Text]
   
4. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599, 2000[Abstract/Free Full Text]
   
5. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor-. J Biol Chem 270:12953–12956, 1995[Abstract/Free Full Text]
   
6. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM: Synthetic peroxisome proliferator-activated receptor- agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376–380, 2002[Abstract/Free Full Text]
   
7. Saito K, Tobe T, Minoshima S, Asakawa S, Sumiya J, Yoda M, Nakano Y, Shimizu M, Tomita M: Organization of the gene for gelatin-binding protein (GBP28). Gene 229:67–73, 1999[Medline]
   
8. Takahashi M, Arita Y, Yamagata K, Matsukawa Y, Okutomi K, Horie M, Shimomura I, Hotta K, Kuriyama H, Kihara S, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord 24:861–868, 2000[Medline]
   
9. Stumvoll M, Tschritter O, Fritsche A, Staiger H, Renn W, Weisser M, Machicao F, Haring H: Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes 51:37–41, 2002[Abstract/Free Full Text]
   
10. Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, Yamauchi T, Otabe S, Okada T, Eto K, Kadowaki H, Hagura R, Akanuma Y, Yazaki Y, Nagai R, Taniyama M, Matsubara K, Yoda M, Nakano Y, Kimura S, Tomita M, Kimura S, Ito C, Froguel P, Kadowaki T: Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 51:536–540, 2002[Abstract/Free Full Text]
    
11. Populaire C, Mori Y, Dina C, Vasseur F, Vaxillaire M, Kadowaki T, Froguel P: Does the –11377 promoter variant of APM1 gene contribute to the genetic risk for type 2 diabetes mellitus in Japanese families? Diabetologia 46:443–445, 2003[Medline]
    
12. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502, 1972[Abstract]
    
13. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I: Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52:1655–1663, 2003[Abstract/Free Full Text]
    
14. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM: The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968–2974, 2002[Abstract/Free Full Text]
    
15. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O’Rahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, Moller DE: Induction of adipocyte complement-related protein of 30 kilodaltons by PPAR agonists: a potential mechanism of insulin sensitization. Endocrinology 143:998–1007, 2002[Abstract/Free Full Text]
    
16. Vasseur F, Helbecque N, Dina C, Lobbens S, Delannoy V, Gaget S, Boutin P, Vaxillaire M, Leprêtre F, Dupont S, Hara K, Clément K, Bihain B, Kadowaki T, Froguel P: Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet 11:2607–2614, 2002[Abstract/Free Full Text]
    
17. Cartegni L, Chew SL, Krainer AR: Listening to silence and understanding non-sense: exonic mutations that affect splicing. Nat Rev Genet 3:285–298, 2002[Medline]
    
18. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:8;941–946, 2001
    
19. Goldfine AB, Kahn CR: Adiponectin: linking the fat cell to insulin sensitivity. Lancet 362:1431–1432, 2003[Medline]
    
20. Yang WS, Hsiung CA, Ho LT, Chen YT, He CT, Curb JD, Grove J, Quertermous T, Chen YD, Kuo SS, Chuang LM, the Sapphire Study Group: Genetic epistasis of adiponectin and PPARgamma2 genotypes in modulation of insulin sensitivity: a family-based association study. Diabetologia 46:977–983, 2003[Medline]
    
21. Kang ES, Yun YS, Park SW, Kim HJ, Ahn CW, Song YD, Cha BS, Lim SK, Kim KR, Lee HC: Limitation of validity of the homeostasis model assessment as an index of insulin resistance in Korea. Metabolism 54:206–211, 2005[Medline]
    
22. Menzaghi C, Ercolino T, Salvemini L, Coco A, Kim SH, Fini G, Doria A, Trischitta V: Multigenic control of serum adiponectin levels: evidence for a role of the APM1 gene and a locus on 14q13. Physiol Genomics 19:170–174, 2004[Abstract/Free Full Text]
    

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				V. G. Kaklamani, M. Sadim, A. Hsi, K. Offit, C. Oddoux, H. Ostrer, H. Ahsan, B. Pasche, and C. Mantzoros Variants of the Adiponectin and Adiponectin Receptor 1 Genes and Breast Cancer Risk Cancer Res., May 1, 2008; 68(9): 3178 - 3184. [Abstract] [Full Text] [PDF]

				C. Menzaghi, V. Trischitta, and A. Doria Genetic Influences of Adiponectin on Insulin Resistance, Type 2 Diabetes, and Cardiovascular Disease Diabetes, May 1, 2007; 56(5): 1198 - 1209. [Abstract] [Full Text] [PDF]

				S. H. Han, M. J. Quon, J.-a Kim, and K. K. Koh Adiponectin and Cardiovascular Disease: Response to Therapeutic Interventions J. Am. Coll. Cardiol., February 6, 2007; 49(5): 531 - 538. [Abstract] [Full Text] [PDF]

				E. S. Kang, B. S. Cha, H. J. Kim, H. J. Kim, S. H. Kim, K. Y. Hur, H. J. Lee, W. S. Shim, C. W. Ahn, and H. C. Lee The 11482G>A Polymorphism in the Perilipin Gene Is Associated With Weight Gain With Rosiglitazone Treatment in Type 2 Diabetes. Diabetes Care, June 1, 2006; 29(6): 1320 - 1324. [Abstract] [Full Text] [PDF]

				J. K. Wolford, K. A. Yeatts, S. K. Dhanjal, M. H. Black, A. H. Xiang, T. A. Buchanan, and R. M. Watanabe Sequence Variation in PPARG May Underlie Differential Response to Troglitazone Diabetes, November 1, 2005; 54(11): 3319 - 3325. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Online-Only Appendix Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kang, E. S. Articles by Lee, H. C. Search for Related Content PubMed PubMed Citation Articles by Kang, E. S. Articles by Lee, H. C. Social Bookmarking                What's this?